No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 ⁦@RheumNow⁩ https://t.co/S3NQ4mWgjt

SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023 https://t.co/Vt58jSXCMd

First Head-to-Head bDMARD study in axSpA to assess radiographic progression - secukinumab vs. adalimumab biosimilar - 66% of either arm prevented radiographic progression - no difference between two arms but good news is radiographic progression is low! @RheumNow #RNL2023 https://t.co/xq8GhN7kzr

Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met. However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC

Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? niche category for IL-17A and F use? @RheumNow #RNL2023 https://t.co/dWkakahHAi

Dennis Poddubnyy #RNL2023 MRI sequences for axSpA: Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression Semi-axial- T2 STIR @RheumNow https://t.co/ySk4hU5lMY

To differentiate mechanical from inflammatory lesion: 1-Site matters 2-Structural changes matter Denis Poddubnyy #RNL2023 ⁦@RheumNow⁩ https://t.co/iQ1gHPnkqO

Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/q3d6kNTVvo https://t.co/FBzZOMVlIK

PAISLEY: Deucravacitinib in SLE #RNL2023 Year in Review DEUC: oral TYK2i P2, 48w DBRCT in active SLE Primary endpt SRI4 at w32 - meets endpt, no dose response Phase 3 study results needed, promising results but JAK studies failed for SLE @RheumNow https://t.co/kKAKHnnG8i

AAV outcomes in patients with diffuse alveolar hemorrhage , ⁦@RheumNow⁩ Kavanaugh #RNL2023 I think i will still use it in sever patients. https://t.co/AEDH4diDuU